The Weekly Recap 7/18/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $67M in new funds, enter new partnerships, and much more on the road to LSI Europe ‘25 in London (September 7-11).

Adtec Healthcare

Secured $12M in funding from two new partners, AIPO Fund and SG Biomedical, to accelerate the global expansion of its Cold Plasma medical technology. The investment will support next-gen device development, U.S. market entry, and broader access to non-invasive wound care and infection control solutions.

Aruna Revolution

Was awarded the first-ever $100K Impact Investment Prize at Startupfest 2025 for its eco-conscious approach to menstrual care products. The Halifax-based startup is developing compostable menstrual pads using absorbent natural fibers to reduce waste from disposable products.

Berlin Heals

Published two-year clinical outcomes showing sustained improvements in heart failure symptoms, function, and quality of life following C-MIC therapy. The results support the long-term safety and potential disease-modifying impact of cardiac microcurrent therapy for heart failure.

Caresyntax

Elevated Matt Krueger, Caresyntax President and former Chief Customer Officer, to Chief Executive Officer, succeeding founders Dennis Kogan and Bjoern von Siemens. Krueger will lead the company’s next phase of global growth and surgical intelligence innovation.

CDX Medical Technologies

Announced the successful close of its $2.5M Series A funding led by Joe Kiani to advance its next-generation ECMO pump. The investment will support regulatory testing, market approval, and the initiation of commercialization.

CustomSurg

Was accepted into the FDA’s TAP Pilot Program, a milestone that validates the potential of its AI-powered surgical planning platform for complex fractures. The designation provides earlier and more frequent FDA engagement, accelerating the company’s path to market leadership in orthopedic trauma care.

Elucid

Appointed Dr. Richard E. Kuntz and Dr. Shamiram Feinglass to its Board of Directors, strengthening leadership in clinical strategy, innovation, and market access. Their guidance will support the commercialization of PlaqueIQ and advance Elucid’s mission to personalize cardiac care through AI-driven plaque analysis.

EndoQuest Robotics

Announced the successful close of a Series D-2 funding round co-led by Crescent Enterprises and Dr. Fred Moll. The new investment will support progress on the pivotal PARADIGM clinical trial, FDA regulatory pathway, upper GI feasibility studies, and progression of advanced endoluminal visualization systems.

GT Medical Technologies

Closed an oversubscribed $53M Series D equity round to accelerate U.S. commercial efforts for GammaTile. The funding will also support enrollment in the company’s ROADS trial for newly diagnosed brain metastases and fund a randomized control trial in newly diagnosed glioblastoma cases.

Hypervision Surgical

Announced a strategic development agreement with imec to co-develop scalable, AI-powered hyperspectral imaging (HSI) systems for surgery. The partnership will combine imec’s on-chip spectral sensing with Hypervision’s real-time, surgery-certified AI analytics to advance precision-guided intraoperative imaging.

InnoTech Precision Medicine

Received a National Science Foundation grant to advance its AI-enabled, saliva-based multiomics diagnostic platform for early detection of head and neck cancer. The funding will support the development of a 30-minute, non-invasive point-of-care test aimed at improving access to early cancer diagnosis.

INNITIUS

Completed the safety pilot phase of its FB-CT2 study ahead of schedule, with over 95% correct measurements and over 90% repeatability. With positive clinician and patient feedback and no significant adverse events, the company will next submit regulatory documentation to begin the efficacy pilot phase of its pivotal study.

Mesh Suture

Achieved MDSAP certification, meeting regulatory standards across the U.S., Canada, Brazil, and Australia. This milestone supports the global expansion of DURAMESH, the company’s flagship surgical closure device designed to improve force distribution and tissue integration.

Neuroelectrics

Was selected in the first 2025 round of the ERC Proof of Concept Grant for its GALVANI SWIFT project, advancing a scalable cloud-based workflow for personalized transcranial electrical stimulation therapy. The project strengthens clinical translation of precision neuromodulation and reinforces Neuroelectrics’ leadership in digital brain health innovation.

Perfuze

Presented preliminary results from the pivotal MARRS trial evaluating the Millipede⁸⁸ aspiration catheter for acute ischemic stroke. Data showed a 77% First Pass Effect for M1 occlusions, 99% delivery success, and a promising safety profile, supporting Perfuze’s plan to submit for FDA approval.

Proximie

Announced two U.S. partnerships advancing real-time surgical connectivity and procedural innovation. The company is supporting Imperative Care’s robotic thrombectomy system and HistoSonics’ Edison Histotripsy System by integrating its platform to enable remote collaboration, improve surgical productivity, and enhance patient outcomes.

Xeltis

Reported positive preliminary data from a European clinical trial of Xabg, its biorestorative coronary artery bypass conduit. The results demonstrate strong safety and patency in patients with multi-vessel atherosclerotic coronary artery disease.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.